Diabetes

Most adults in the United States with physical chronic health conditions manage them at work but have not told their employer about them, results from a national survey showed.

The FDA has removed semaglutide from its drug shortage list after the agency determined the current supply of the drug can meet present and future demand, Novo Nordisk and the FDA announced.

The presentation of Cushing’s disease varies by age, with older adults having fewer hallmark features of the condition and more comorbidities, according to study findings published in The Journal of Clinical Endocrinology & Metabolism.

Glomerular hyperfiltration may increase CVD risks, including myocardial infarction and heart failure, for patients with type 2 diabetes, study data show.

The prevalence of diabetes is increasing faster in some low-income countries than elsewhere in the world, generating concerns about health care infrastructure and access to treatment for people in those regions.

The FDA has approved the first rapid-acting biosimilar insulin product for glycemic control in people with diabetes.

The GLP-1 liraglutide showed potential benefit in reducing stroke recurrence and improving functional outcomes after minor stroke or transient ischemic attack, a speaker reported.

As the body of research expands on the potential of glucagon-like peptide-1 receptor agonists to address various health issues, recent data suggest they may improve brain health.

Among patients with type 2 diabetes, use of GLP-1 agonists may increase the risks for adhesive capsulitis and required surgical intervention, such as manipulation under anesthesia, according to published results.

Sodium-glucose cotransporter 2, or SGLT2, inhibitors and glucagon-like peptide-1 receptor agonists lowered the risk for COPD exacerbation in adults with the disease and type 2 diabetes, researchers reported.